GlassScriptPhysician profile
Jonathan R Levy
NPI 1114456910
$7,683.67
in general payments reported to CMS, 2019-2025
39 companies · $1,972 in 2025
The $1,972 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,134 · 2022: $1,446 · 2023: $1,799 · 2024: $1,333 · 2025: $1,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,103.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $772.76 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $646.70 | 2021-2025 | Mounjaro, Emgality, Reyvow |
| Collegium Pharmaceutical, INC. | $557.17 | 2021-2025 | Belbuca |
| Pfizer INC. | $491.62 | 2021-2025 | |
| Axsome Therapeutics, INC. | $473.32 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $469.05 | 2022-2025 | Rexulti, Abilify Mycite |
| Neurocrine Biosciences, INC. | $392.49 | 2023-2025 | Ingrezza |
| Novo Nordisk INC | $363.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Idorsia Pharmaceuticals US INC | $359.33 | 2022-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $253.95 | 2021-2025 | Seglentis, Zoryve, Livalo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $211.82 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.25 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $184.51 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $178.35 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.